about
Selective serotonin re-uptake inhibitors and the risk of bleedingDSM-5 criteria for substance use disorders: recommendations and rationaleValidity of the Adult ADHD Self-Report Scale (ASRS) as a screener for adult ADHD in treatment seeking substance use disorder patients.Psychiatric comorbidity in treatment-seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study.Variability in the prevalence of adult ADHD in treatment seeking substance use disorder patients: results from an international multi-center study exploring DSM-IV and DSM-5 criteria.[Benzodiazepine withdrawal in subjects on opiate substitution treatment].[Cannabis and psychosis: search of a causal link through a critical and systematic review].Risk Factors for Borderline Personality Disorder in Treatment Seeking Patients with a Substance Use Disorder: An International Multicenter Study.Why buprenorphine is so successful in treating opiate addiction in France.An overview of and rationale for changes proposed for pathological gambling in DSM-5A socio-structural approach to preventing injection drug use initiation: rationale for the PRIMER study.Relationship between anxiety disorders and opiate dependence--a systematic review of the literature: implications for diagnosis and treatment.Effectiveness of therapeutic communities: a systematic review.The diagnostic accuracy of attention-deficit/hyperactivity disorder in adults with substance use disorders.Ecological momentary assessment in the investigation of craving and substance use in daily life: a systematic review.Mortality Associated With Time in and Out of Buprenorphine Treatment in French Office-Based General Practice: A 7-Year Cohort Study.Addiction severity pattern associated with adult and childhood Attention Deficit Hyperactivity Disorder (ADHD) in patients with addictions.Analyses related to the development of DSM-5 criteria for substance use related disorders: 3. An assessment of Pathological Gambling criteria.Borna disease virus RNA in immunocompromised patients in southwestern France.French field experience with buprenorphine.Association between morningness/eveningness, addiction severity and psychiatric disorders among individuals with addictions.A randomized double-blind study of neuroelectric therapy in opiate and cocaine detoxification.Craving and substance use among patients with alcohol, tobacco, cannabis or heroin addiction: a comparison of substance- and person-specific cues.The DSM-5 field trials and reliability of alcohol use disorder.Change in HIV-HCV risk-taking behavior and seroprevalence among opiate users seeking treatment over an 11-year period and harm reduction policy.Self-perceived motivation for benzodiazepine use and behavior related to benzodiazepine use among opiate-dependent patients.Social phobia and premature ejaculation: a case-control study.Sensation seeking as a common factor in opioid dependent subjects and high risk sport practicing subjects. A cross sectional study.Ecological momentary assessment in alcohol, tobacco, cannabis and opiate dependence: a comparison of feasibility and validity.Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: correlates of use, abuse and dependence.Examining the influence of drop-outs in a follow-up of maintained opiate users.Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus.Griffiths et al.'s comments on the international consensus statement of internet gaming disorder: furthering consensus or hindering progress?Cerebral blood flow modulation by transcutaneous cranial electrical stimulation with Limoge's current.Transcutaneous electrical stimulation with Limoge current potentiates morphine analgesia and attenuates opiate abstinence syndrome.Predictors of craving and substance use among patients with alcohol, tobacco, cannabis or opiate addictions: Commonalities and specificities across substances.Moving internet gaming disorder forward: A reply.Internet gaming and addiction: a reply to King & Delfabbro.An international consensus for assessing internet gaming disorder using the new DSM-5 approach.Use of midazolam for ECT anesthesia: effects on antidepressive efficacy and seizure duration. Preliminary findings.
P50
Q28211440-40D60235-AA11-4A4E-81BB-09B567264574Q30544314-ED84FEA3-4194-432E-AC19-C35BA260F653Q33851850-9D9F9F00-A64D-4F0F-98E8-2FCA241EA12FQ33957119-654B7BE2-4071-48F9-AF59-8B494563766EQ34049049-F6159C62-D73A-48DA-812E-16F9A0685CE2Q34513898-359746F1-BA17-43C0-A423-13C4E5D91480Q34611771-FC6D3FC9-6985-434B-916E-C532A4C9AFCBQ36908238-361B8E90-C51A-47E5-BDFF-264D4346AF0CQ36960169-092D3416-3762-4782-9BA2-FC52FDE67E8CQ37042976-169BE59D-2611-4646-A56B-AE0E0456331AQ37258183-AA947AAB-A0EE-4A29-97FA-F0FF7A0F09A8Q37684275-19A50702-2291-49F1-A2F4-AB234AFE77F5Q37945507-1DB0C8FC-B501-42BC-95E7-E3C8C1DD899FQ37997189-F88FB546-7151-4778-8267-C65BB7EAF71DQ38338253-7A9C790D-9993-48B3-9CB0-FF26DF01B0F1Q38685426-9932FE6E-F675-4D02-857F-E3775B35C145Q39188761-77D2F2FE-024F-4296-8FFF-61659C560F20Q39702106-18E9FEBC-A0DE-4E65-B9A4-D84A1E2DB9F2Q40404138-85B17BF8-C871-4623-B0D0-F206EC8452D8Q40502352-48260B86-10B2-4F73-940A-77B9F7970E4FQ40651080-F1AA9482-CA79-43A6-B1B7-7C2F3A4EF69FQ41131510-9FF769D6-A2D6-48F1-A139-8D0A0ACB8B8CQ41420189-C7358470-1CE2-46A6-A547-92CF3FAB28DDQ41865972-1DCCC977-70B6-40B1-B0F1-6C8023BD7618Q42619415-4866EBBF-DE79-44E6-9EE8-52F239404536Q43838712-2ACF9EF1-2F0A-4BDA-807C-C5DF3FD1053CQ44274092-94DBADF4-518A-4599-9197-53B6C0A2A408Q44332660-EC3C9488-97F8-45B7-93B8-9B2CA748A614Q44910543-43850018-D88F-4CA0-9D83-4966F9AB820CQ45401403-A66738E4-8BCB-437C-B91B-AE47CF8A46BAQ46651925-AAD324AA-9507-43D4-AC2B-4B821D05CB13Q47569876-4C84518C-230B-4A59-8B9E-7C585E3B9701Q48088150-40929171-144F-4681-93D3-6BB5B17FB98EQ48239121-B29F4C5A-D4AC-4A46-A77C-A821CA13748DQ48879335-F552B735-0BCB-417F-85EF-459BAB123FE5Q50083669-C413D99D-DF80-470E-84F0-D39CD7D2BDA8Q50629066-CD06F672-9D64-4248-8AEA-BC25C988AA40Q50649117-092CE341-8A1B-415D-9A27-F45264DF5EC7Q50664005-43970763-D00C-484A-95AD-7A5FC83C5D8AQ51612905-A9292C4A-8E72-4E35-947D-1AC1B7E78A80
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Marc Auriacombe
@ast
Marc Auriacombe
@en
Marc Auriacombe
@es
Marc Auriacombe
@sl
type
label
Marc Auriacombe
@ast
Marc Auriacombe
@en
Marc Auriacombe
@es
Marc Auriacombe
@sl
altLabel
Auriacombe M
@en
prefLabel
Marc Auriacombe
@ast
Marc Auriacombe
@en
Marc Auriacombe
@es
Marc Auriacombe
@sl
P214
P1053
A-6197-2017
P106
P1153
7006948565
P21
P214
P2798
P31
P3829
P3835
marc-auriacombe2
P496
0000-0002-8938-8683
P735
P7859
viaf-51786594